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Mutations of the von Hippel-Lindau (VHL) tumor suppressor gene occur in the majority of
sporadic renal-cell carcinomas (RCC). Loss of VHL function is associated with stabilization
of hypoxia-inducible factor α (HIFα). We and others demonstrated that there is a two-way
interaction between the aryl hydrocarbon receptor, which is an important mediator in the
metabolic activation and detoxification of carcinogens, and the HIF1-pathway leading to an
increased genetic instability when both pathways are simultaneously activated. The aim
of this study was to investigate how environmental carcinogens, such as benzo[a]pyrene
(BaP), which can be metabolically activated to BaP-7,8-diOH-9,10-epoxide (BPDE) play a
role in the etiology of RCC. We exposed VHL-deficient RCC4 cells, in which HIFα is sta-
bilized regardless of oxygen tension, to 0.1µM BaP for 18 h. The mutagenic BPDE-DNA
adduct levels were increased in HIFα stabilized cells. Using qRT-PCR, we demonstrated
that absence of VHL significantly induced the mRNA levels of AhR downstream target
CYP1A1. Furthermore, HPLC analysis indicated that loss ofVHL increased the concentration
of BaP-7,8-dihydroxydiol, the pre-cursor metabolite of BPDE. Interestingly, the capacity to
repair BPDE-DNA adducts in the HIFα stabilized RCC4 cells, was markedly reduced.Taken
together, these data indicate that loss of VHL affects BaP-mediated genotoxic responses
in RCC and decreases repair capacity.
Keywords: nucleotide excision repair, metabolism, carcinogens, renal-cell carcinoma, von Hippel-Lindau
INTRODUCTION
Renal-cell carcinoma (RCC) is the most common type of kid-
ney cancer in adults and accounts for 4% of all cancers (1). The
most frequently observed genetic alteration in RCC is the somatic
mutation of the von Hippel-Lindau (VHL) tumor suppressor
gene (2, 3).
The VHL protein (pVHL) is a crucial regulator of the oxygen
sensing pathway, which involves the transcription factor hypoxia-
inducible factor alpha (HIFα) (2, 4). In the presence of oxygen,
HIFα is hydroxylated by an oxygen-dependent prolyl hydroxy-
lase (HIF-PH) (5). An E3 ubiquitin ligase complex containing
the pVHL recognizes the hydroxylated HIFα, and targets it for
ubiquitination (6) and subsequently proteasomal degradation (7).
Under hypoxic conditions, HIFα is not prolyl-hydroxylated and
thus unrecognized by pVHL.
The stabilized HIFα can translocate to the nucleus where it
forms a heterodimer with HIF1β, also referred to as aryl hydrocar-
bon receptor nuclear translocator (ARNT) (8). HIF1 then binds
to the promoter/enhancer regions in the DNA (9), where it dri-
ves the expression of a wide array of hypoxia-inducible genes to
augment oxygen delivery or to provide alternative pathways for
energy production and cell metabolism.
The functional loss of pVHL in some RCC results in an aberrant
stabilization of HIFα independent of the oxygen tension. The sub-
sequent overexpression of proteins encoded by HIFα regulated
target genes contributes to the creation of a microenvironment
favorable for cell proliferation (2, 10–12).
In many tumors including RCC, the hypoxia-responsive tran-
scription factor HIFα is overexpressed (13),and patients diagnosed
with such hypoxic tumors will often have a poor clinical prog-
nosis due to the formation of metastases and the resistance to
chemotherapeutics (14). This negative prognosis may occur due to
low oxygen concentrations having the capacity to induce genetic
instability, leading to increased rates of mutagenesis and angio-
genesis, decreased rates of apoptosis and upregulation of genes
involved in the metastatic cascade (15). Suppression of the DNA
damage response pathways within the hypoxic tumors may also
play a critical role (9).
In addition to forming a complex with HIFα, HIF1β/ARNT
also dimerizes with the aryl hydrocarbon receptor (AhR) which is
known to interact with environmental pollutants such as dioxins
and polycyclic aromatic hydrocarbons (PAH). PAHs are widely
distributed contaminants produced as byproducts of combustion
processes such as in vehicle exhaust, cigarette smoking, and char-
coal grilling of food. Benzo[a]pyrene (BaP) is a classic example of
PAH and is readily absorbed by inhalation, ingestion, and through
the skin. As BaP is lipophilic, it can easily diffuse into cells where
it binds to AhR, translocates into the nucleus and subsequently
heterodimerizes with HIF1β/ARNT. This complex can then bind
to the xenobiotic response elements of target genes (16) where it
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acts as a transcription factor for a number of genes, which encode
for enzymes involved in xenobiotic detoxification, including the
cytochrome P450 (CYPs) isoforms CYP1A1 and CYP1B1 (17, 18).
The detoxification process of BaP begins with an epoxida-
tion reaction by the mono-oxygenases CYP1A1 and CYP1B1
(phase I). The resulting metabolites (e.g., BaP-7,8-epoxide and
BaP-9,10-epoxide) can be converted non-enzymatically to phe-
nols (e.g., 3-OH BaP) or enzymatically to dihydrodiols (e.g.,
BaP-7,8-diOH or BaP-9,10-diOH) by epoxide hydrolase. Phenols
can subsequently be converted to water-soluble sulfate or glu-
curonide conjugates (phase II) and dihydrodiols can be further
transformed by CYP1A1 or CYP1B1 to diol epoxides [e.g., BaP-
7,8-diol-9,10-epoxide (BPDE)] or conjugated by uridine diphos-
phate glucuronosyl transferase (UGT) (18). An unfortunate con-
sequence of the detoxification reaction is the production of the
intermediate BPDE, which can covalently bind to DNA form-
ing highly mutagenic DNA adducts (17). When unrepaired, these
lesions may result in mutations (19).
Previously, we demonstrated that exposure of cells to hypoxia
markedly enhances the genetic instability caused by exogenous
genotoxins and that HIF activation decreases nucleotide excision
repair (NER) (20). Furthermore,we demonstrated that the kinetics
of BaP metabolism is altered under hypoxia resulting in a pro-
longed time of exposure and a higher amount of BPDE-DNA
adducts being formed (Schults et al. manuscript submitted for
publication). From these initial studies in which we induced HIFα
expression using chemicals or hypoxia, we observed an important
link between the HIF1 mediated response pathway and the cellular
response pathway that counteracts chemical carcinogens.
In the present study, we hypothesize that in naturally occurring
RCC cells that have a defect in HIF regulation, the observed genetic
instability may be the result of a faulty response to environmen-
tal carcinogens such as BaP. In this current report, we show that
loss of VHL affects BaP-mediated genotoxic responses by induc-
ing CYP1A1 mRNA levels, which mediated a significant change in
BaP-7,8-diOH, the pre-cursor metabolite of BPDE. Secondly, the
capacity to repair DNA by NER is reduced in these cells, thereby
preventing the repair of those BPDE-DNA adducts.
MATERIALS AND METHODS
CELL CULTURE AND TREATMENT
RCC4 (VHL−/−) cells, a VHL-deficient cell line and RCC4-VHL
(VHL+/+), RCC4 reconstituted with VHL, were cultured in Dul-
becco’s Modified Eagle Medium (DMEM; Sigma-Aldrich, UK)
supplemented with 10% heat-inactivated Fecal Calf Serum (FCS;
Invitrogen Breda, The Netherlands) and 1% penicillin strepto-
mycin (P/S; Gibco, Invitrogen, Paisley, UK) at 37°C in a 5% CO2
and 20% O2 atmosphere. Cells were seeded 1 day before treat-
ment and maintained at 37°C in a 5% CO2 atmosphere. All cells
were treated with 0 or 0.1µM BaP (Sigma) dissolved in DMSO
(final concentrations did not exceed 0.5%) for 18 h. After treat-
ment medium was removed and cells were harvested using trypsin.
All samples were stored at−20°C.
QUANTITATIVE REAL-TIME PCR
Cells were washed twice with PBS and lysed with Trizol (Invit-
rogen). Total RNA was isolated according to the manufacturer’s
instructions. The quantity of each RNA sample was spectropho-
tometrically assessed by a Nanodrop 1000 (Thermo Scientific,
Waltham, MA, USA). cDNA synthesis was performed using the
iScript cDNA Synthesis kit (Biorad, Veenendaal, The Netherlands)
starting with 1µg of RNA. cDNA was diluted 25× in RNase free
water. Real-time PCR was performed using the MyiQ Single Color
RT-PCR detection system (Biorad) using Sensimix Sybr Green
(Quantace, London, UK), 5µl diluted cDNA and 0.3µM (Table 1)
primers in a total volume of 25µl. Samples were amplified under
the following conditions: 95°C for 3 min, followed by 40 cycles of
95°C for 15 s and 60°C for 45 s. PCR was checked for a-specific
products by performing a melting curve analysis (65–95°C). Data
were analyzed using the MyiQ Software system (Biorad) and were
expressed as relative gene expression (fold increase) using the
2−∆∆Ct method. The stably expressed gene cyclophilin A was
included as reference.
DNA ISOLATION
Cells were harvested and resuspended in 400µl SET/SDS (100 mM
NaCl, 20 mM EDTA, 50 mM Tris, 0.5% SDS) and incubated at
37°C for 2 h. About 50µl of DNAse-free RNAse-solution [RNAse
A (0.1 mg/ml) and RNAse T1 (1000 U/ml) in SET, incubated at
80°C for 5 min] was added and samples were incubated at 37°C for
1 h followed by adding 50µl DNAse-free proteinase K (10 mg/ml
in SET-SDS, heat-inactivated at 37°C for 30 min) and samples
were incubated overnight at 37°C. After addition of 500µl phe-
nol/chloroform/Isoamylalcohol (25:24:1), samples were rotated
Table 1 | Primer sequences for real-time RT-PCR.






CYP1A1 Forward TCCTGGAGACCTTCCGACACT NM_000499.3
Reverse CTTTCAAACTTGTGTCTCTTGTTGTG
CYP1B1 Forward AGTGCAGGCAGAATTGGATCA NM_000104.3
Reverse GCGCATGGCTTCATAAAGGA
XPA Forward CCGACAGGAAAACCGAGAAA NM_000380.3
Reverse TTCCACACGCTGCTTCTTACTG
XPC Forward CCCAGCCCGCTTTACCA NM_004628.4
Reverse TGCATTAACTGTAAATGTTCCAATGA
ERCC4 Forward CACCTCCCTCGCCGTGTA NM_005236.2
Reverse CGCAAATATAACACCACCTTGTG
ERCC5 Forward GCATGAAATCTTGACTGATATGAAAGA NM_000123.3
Reverse TAAGCAAGCCTTTGAGTTGGTACTG
ERCC1 Forward ACCCCTCGACGAGGATGAG NM_202001.2
Reverse CAGTGGGAAGGCTCTGTGTAGA
GSTP1 Forward CTCAAAAGGCTTCAGTTGCC NM_000852.3
Reverse ACCTCCGCTGCAAATACATC
EPHX1 Forward CTTCACGTGGATGAAGTGGA NM_000120.3
Reverse CTGGCGGAATGAATTTGACT
UGT1A6 Forward GGAACCCGACCATCGAATC NM_001072.3
Reverse TCGGGTGACCAAGCAGATC
UGT2B7 Forward TCCCATCAAATCTCCACAGA NM_001074.2
Reverse GGTGTTTTCTCTGGGGTCAA
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for 5 min and centrifuged for 5 min at 14000 rpm. To the upper-
phase, 500µl chloroform/Isoamylalcohol (24:1) was added and
samples were 5 min rotated, centrifuged for 5 min (14000 rpm)
and 1/30 volume NaAc (3 M, pH 5.2) was added to the upperphase.
Samples were mixed for a few seconds and two volumes ethanol
100% (4°C) were added, samples were mixed and incubated at
−20°C for 30 min. Samples were centrifuged for 5 min and DNA
pellets were washed with ethanol 70%. DNA pellets were dried and
resuspended in Mili-Q H2O. The quantity and quality of DNA was
measured using the Nanodrop 1000.
32P-POSTLABELING OF BPDE-DNA ADDUCTS
DNA adduct levels were determined according to the nuclease
P1 enrichment technique originally described by Reddy and Ran-
derath (21) with the modifications described by Godschalk et al.
(22). In all experiments, three BPDE-DNA standards with known
BPDE-DNA adduct levels (one adduct per 106, 107, and 108
normal nucleotides) were analyzed in parallel for quantification
purposes. Adducts spots in DNA from BaP treated RCC4 cells
that chromatographed at the same position as the BPDE-DNA
adducts standards were considered to be derived from BPDE,
and were quantified using Phosphor-Imaging technology (Fujifilm
FLA-3000, Rotterdam, The Netherlands).
HPLC
In order to determine BaP-metabolite composition, 4 ml medium
was extracted with 1 ml ethyl acetate after addition of 1 ml 3 M
NaCl. Samples were vortexed for 10 min, centrifuged for 5 min at
1000 rpm and after briefly vortexed, centrifuged again for 10 min
at 1500 rpm. The ethyl acetate fraction was collected and the
extraction step was repeated twice. The second time and third
time, only ethyl acetate was added and the third time, also two
droplets of ethanol were added to the samples for better sep-
aration. The ethyl acetate fractions were combined, evaporated
to dryness under N2, and residues were resuspended in 0.5 ml
methanol. For chromatographic separation, a 50µl volume of
the sample was injected onto a Hypersil 5µm ODS HPLC col-
umn (250 mm× 3 mm i.d.) (Supelco 54933, Bellefonte, PA, USA)
at a flow rate of 0.5 ml/min. Mobile phase A and B were 100%
methanol (Biosolve Chemicals, Valkenswaard, The Netherlands)
and 40% methanol in water, respectively. The time program for
the multi-step gradient was: 0–5 min: isocratically 40/60 (A/B,
v/v), 5–30 min: gradient from 40/60 (A/B, v/v) to 90/10 (A/B,
v/v), 30–35 min: isocratically 90/10 (A/B, v/v), 35–37 min: gra-
dient from 90/10 (A/B, v/v) to 40/60 (A/B, v/v), 37–40 min:
40/60 (A/B, v/v). The total run time was 40 min. For quantita-
tion purposes, a standard mix consisting of 50 ng/ml BaP-9,10-
diOH, 50 ng/ml BaP-7,8-diOH, and 50 ng/ml 3-OH BaP (Midwest
Research Institute, Kansas City, MO, USA) was used. Samples
were analyzed on a Gynkotek P580A HPLC system (Separations
Analytical Instruments, Hendrik Ido Ambacht, The Netherlands)
with a Spark SP830 autosampler (Spark Holland, Emmen, The
Netherlands) and a Perkin Elmer LS-30 programmable fluores-
cence detector (Perkin Elmer, Foster City, CA, USA). Excita-
tion/emission wavelengths were 257/>350 nm. For quantifica-
tion, the area of each metabolite peak on the chromatogram was
determined.
MEASUREMENT OF REPAIR CAPACITY
To assess NER capacity in the liver samples, we applied a well
characterized and validated modified comet assay (23). This assay
measures the ability of NER-related enzymes that are present
in cell extracts, to incise substrate DNA containing BPDE-DNA
adducts. The substrate nucleoids were prepared from untreated
A549 cells (human epithelial lung carcinoma cells) obtained from
the American Tissue Culture Collection (ATCC, Rockville, MD,
USA). The cells were cultured in DMEM supplemented with
10% heat-inactivated FCS and 1% penicillin/streptomycin and
maintained at 37°C in a 5% CO2 atmosphere. A549 cells were
embedded in LMP agarose on glass microscope slides and sub-
sequently lyses overnight in cold (4°C) lysis buffer (2.5 M NaCl,
0.1 M EDTA, 0.01 M Tris, 0.25 M NaOH plus 1% Triton X-100 and
10% DMSO). The resulting nucleoids were then either exposed
to 1µM BPDE (NCI Chemical Carcinogen Reference Standard
Repository, Midwest Research Institute, Kansas City, MO, USA)
in PBS or vehicle control (DMSO, 0.5%) for 30 min at 4°C. To
prepare protein/enzyme extracts, RCC4 and RCC4-VHL cells were
harvested and resuspended in buffer A (45 mM HEPES, 0.4 M KCl,
1 mM EDTA, 0.1 mM dithiothreitol, 10% glycerol, adjusted to pH
7.8 using KOH). Resulting aliquots were snap-frozen, thawed again
and 30µl of 1% Triton X-100 in buffer A per 100µl of extract was
added. Protein concentrations were determined by the BioRAD
DC protein assay using bovine serum albumin as a standard. Tis-
sue extracts were diluted to a concentration of 1 mg/ml. Next, four
volumes of reaction buffer B (45 mM HEPES, 0.25 mM EDTA, 2%
glycerol, 0.3 mg/ml BSA, adjusted to pH 7.8 with KOH) were added
and 50µl of the mixture was added to the gel-embedded nucleoids
and incubated for 20 min at 37°C. Alkaline treatment (40 min)
and electrophoresis (30 min) were conducted as described in the
standard comet assay (24). Comets were visualized using a Zeiss
Axioskop fluorescence microscope and quantified as tail moment.
Samples were tested in two independent incubations within each
single experiment. On every slide, 50 cells were analyzed randomly
using the Comet assay III software program (Perspective Instru-
ments, Haverhill, UK). The increased DNA strand breakage (tail
moment) in the BPDE-modified nucleoids vs. the DMSO-treated
nucleoids is indicative for the NER capacity of the cell extracts. The
final repair capacity was calculated according to Langie et al. (23).
STATISTICAL ANALYSIS
Results are expressed as the mean± SE of the mean. GraphPad
Prism 4 was used for statistical analysis. A two-way analysis of
variance (ANOVA) with Bonferroni post hoc multiple compari-
son correction was used to assess differences in mRNA levels. To
analyze differences in, metabolite levels, adduct levels, and repair
capacity a Student’s t -test was used. Differences were considered
to be statistically significant when P < 0.05.
RESULTS
BPDE-DNA ADDUCT LEVELS ARE HIGHER IN CELLS DEFICIENT IN VHL
To examine the influence of VHL deletion on BaP-mediated geno-
toxic responses, we quantified the amount of BPDE-DNA adducts
in VHL-deficient RCC4 cells and compared it with the geneti-
cally wild type RCC4-VHL cells and normalized it to the total
amount of DNA (Figure 1). Exposure to 0.1µM BaP resulted in

























































Schults et al. Loss of VHL induces BaP genotoxicity
FIGURE 1 | BPDE-DNA adduct levels are higher in cell deficient inVHL.
RCC4-VHL and RCC4 cells were incubated with 0.1µM BaP. DNA was
isolated after 18 h and BPDE-DNA adduct levels were measured by
32P-postlabeling. Data (n=4) are presented as mean adduct level per 107
nucleotides±SE (*P <0.05, Student’s t -test).
a ∼1.7-fold greater formation of the pro-mutagenic BPDE-DNA
adduct in RCC4 cells, compared to RCC4-VHL cells (P < 0.05).
CELLS DEFICIENT IN VHL HAVE CHANGES GENE EXPRESSION OF
METABOLIC ENZYMES
Since metabolism may be the underlying cause of the increase
in BPDE-DNA adducts in cells deficient in VHL, we assessed
the mRNA expression of several key phase I and II metabolic
enzymes. Of the phase I enzymes responsible for the activation
of BaP, CYP1A1 mRNA levels significantly differ between the two
cell lines (Figure 2A). The CYP1A1 mRNA levels were ∼31 and
∼5.8 times higher in the RCC4 cells compared to the RCC4-VHL
cells (P < 0.01), for untreated and BaP treated cells, respectively.
CYP1B1 gene expression was not statistically different between
the two cell lines (Figure 2B). Gene expression of four phase II
enzymes responsible for the conjugation of BaP metabolites was
also measured. The expression of the glutathione S-transferases
GSTP1 was ∼24% lower in RCC4 cells compared to RCC4-VHL
cells (P < 0.05, Figure 3A). Epoxide hydrolase 1 (Figure 3B) and
the UDP glucuronosyltransferases UGT1A6 (Figure 3C) showed
no difference between the two cell lines. Conversely, UGT2B7
expression was ∼1.5 and 1.6 times higher (DMSO and BaP treat-
ment respectively) in RCC4 cells compared to the RCC4-VHL cells
(Figure 3D).
ABSENCE OF VHL DIRECTS BaP METABOLISM TOWARD UNFAVORABLE
ACTIVATION
To determine whether the observed differences in BaP meta-
bolic enzymes between the two cell lines resulted in the expected
detrimental changes in BaP metabolism, we assessed BaP and
its metabolites BaP-9,10-diOH, BaP-7.8-diOH and 3-OH BaP by
HPLC analysis with fluorescence detection. RCC4 and RCC4-VHL
were exposed for 18 h to 0.1µM BaP and the medium was col-
lected. The rate of metabolism was determined from measuring
the remaining amount of unmetabolized BaP. In the medium, a
non-statistically significant∼twofold higher level of BaP was mea-
sured in the RCC4 cells compared to the control RCC4-VHL cells
(Figure 4A). For all three metabolites assessed, statistically signif-
icant higher levels of metabolites were found in the medium of
the RCC4 cells compared to the RCC4-VHL cells. A ∼1.7- and
FIGURE 2 | CYP1A1 but not CYP1B1 mRNA expression, is markedly
enhanced inVHL defective cells. RCC4-VHL () and RCC4 cells () were
incubated with DMSO or 0.1µM BaP for 18 h. RNA was isolated and
mRNA levels were measured of (A) CYP1A1 and (B) CYP1B1. Data (n=4)
are presented as mean fold change±SE (**P <0.01).
2.7-fold induction of BaP-9,10-diOH and 3-OH BaP, respec-
tively, was observed in RCC4 cells compared to RCC4-VHL cells
(Figures 4B,C). Furthermore, compared to RCC4-VHL cells, BaP-
7,8-diOH levels, the BPDE pre-cursor, were ∼2.9 times higher in
RCC4 cells (Figure 4D).
NUCLEOTIDE EXCISION REPAIR CAPACITY IS REDUCED IN
VHL-DEFICIENT CELLS
As we previously reported a downregulation of NER capacity in
HIFα stabilized cells, we sought to determine whether dimin-
ished DNA repair may also play a role in the observed differences
in BPDE-DNA adduct levels induction between the RCC4 and
RCC4-VHL cells. Firstly, we determined the influence of DNA
repair gene expression in the matched cells. The mRNA levels of
the critical NER genes XPA, XPC, ERCC1, ERCC5, and ERCC4
were not altered in the cell lines (Table 2). Secondly, as DNA
repair is often not regulated at the transcription level, we used a
validated modified comet assay to determine the functional NER
capacity. A markedly reduced repair capacity was observed in the
VHL-deficient cells compared to the reconstituted RCC4-VHL
cells (Figure 5).
DISCUSSION
Previously, we demonstrated that the stabilization of HIFα by
CoCl2 enhanced the carcinogenic effect of BaP in lung cancer
cells and reduced repair (20). Furthermore, we demonstrated
that the kinetics of carcinogen metabolism altered under hypoxic
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FIGURE 3 | Loss ofVHL increases UGT2B7, but decreases GSTP1 gene
expression. RCC4-VHL () and RCC4 cells () were incubated with DMSO
or 0.1µM BaP for 18 h. RNA was isolated and mRNA levels were measured
of (A) GSTP1, (B) EPHX1, (C) UGT1A6, and (D) UGT2B7. Data (n= 4) are
presented as mean fold change±SE (**P <0.01, ***P <0.001, two-way
ANOVA with Bonferroni post hoc multiple comparison correction).
FIGURE 4 | Absence ofVHL decreased BaP metabolism, but increased
BaP metabolites. RCC4-VHL () and RCC4 cells () were incubated with
0.1µM BaP for 18 h and extracellular unmetabolized BaP (A), BaP-9,10-diOH
(B), BaP-7,8-diOH (C), and 3-OH BaP (D) metabolites were measured. Data
(n=5) are presented as mean area under the curve±SE (*P <0.05,
**P <0.01; Student’s t -test).
conditions, resulting in more BPDE-DNA adducts being formed
(Schults et al. manuscript submitted for publication). The aim
of the current study was to determine whether similar genetic
instability mechanisms hold true in the naturally occurring
VHL-deficient RCC cells. In this report, we demonstrate that the
loss of VHL and via presumably the stabilization of HIFα, affects
both genetic stability related processes of BaP-mediated and DNA
repair capacity in RCC cells.
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Table 2 | Relative NER gene expression.
BaP XPA XPC ERCC4 ERCC5 ERCC1
0µM RCC4-VHL 1.00±0.02 1.00±0.14 1.00±0.08 1.00±0.10 1.00±0.09
RCC4 0.94±0.05 0.98±0.12 0.98±0.03 1.16±0.11 1.09±0.06
0.1µM RCC4-VHL 1.02±0.04 1.04±0.16 0.95±0.08 0.98±0.08 1.01±0.02
RCC4 1.15±0.05 1.17±0.19 0.89±0.02 1.21±0.12 1.17±0.09
Statistical method used: two-way ANOVA with Bonferroni post hoc multiple comparison correction.
FIGURE 5 | NER capacity is decreased in RCC4 cells. The ability to repair
BPDE-DNA adducts in RCC4-VHL and RCC4 cells were measured using the
modified comet assay (23). Data (n=4) are presented as mean fold
change±SE (*P <0.05, Student’s t -test).
Cytochrome P450 enzymatically converts BaP into BPDE. This
active metabolite subsequently binds DNA covalently forming
highly mutagenic DNA adducts (17). To investigate the effect
of metabolically activated BaP on RCC4 cells, the formation of
BPDE-DNA adducts was determined. Our data demonstrated that
VHL deficiency resulted in increased BPDE-DNA adduct levels
in RCC4 cells, compared to RCC4-VHL cells, when treated with
0.1µM BaP. This is in agreement with our previously observed
results, where the formation of BPDE-DNA adducts was increased
due to stabilization of HIFα by CoCl2 in A549 cells (20).
To determine whether metabolism may be the cause of
the increased BPDE-DNA adduct levels in VHL-deficient cells
changes in gene expression of relevant enzymes in the metab-
olism of BaP were assessed. CYP1A1 and CYP1B1 are two of
the most important enzymes in the detoxification and bioac-
tivation of BaP (17, 18). Furthermore, CYP1A1 is the critical
enzyme in the bioactivation of BaP-7,8-diOH to the ultimate car-
cinogenic BPDE metabolites in human lung cell lines in vitro
(25). In this study, we demonstrate that CYP1A1 mRNA lev-
els were strongly upregulated in the HIFα stabilized RCC4 cells
compared to the reconstituted genetically wild type cells. As
CYP1B1 mRNA levels were unaffected by VHL loss, CYP1A1
appears to be the critical player in RCC metabolism of BaP in
these cells. Induction of CYP1A1 in HIFα-stabilized cells may
result in an increased level of BPDE formation, which may
subsequently induce carcinogenicity. This observation compares
well with studies in other cell types where CYP1A1 activity
has been positively correlated with pulmonary PAH (BPDE)-
associated DNA adduction (26), and high CYP1A1 inducibility
in lymphocytes has been related to a high lung cancer risk
(27, 28).
The resulting metabolites of BaP can be converted into
hydrophilic products by phase II enzymes (18). Alterations in these
conjugation reactions result in changed elimination of these com-
pounds and subsequently BPDE-DNA adducts level. No pattern
was observed for phase II enzymes, suggesting that they are not
likely involved in the observed different BPDE-DNA adduct levels
identified between the two cell lines. Nevertheless, measuring BaP
metabolites provides a better insight into differences in BaP metab-
olism between the two RCC4 cell lines. BaP-9,10-diOH was the
most abundant metabolite present in the media of both cell lines.
This metabolite subsequently forms BaP-9,10-diol-7,8-epoxide,
which importantly is far less carcinogenic than BPDE. We further
observed that the increased levels of metabolites and in particu-
lar BaP-7,8-diOH, which can be oxidized to BPDE, correlates well
with the observed increased DNA adducts levels. Together, these
data indicate thatVHL-deficient RCC cells are able to differentially
bioactivate BaP as compared to the reconstituted RCC4-VHL cells
suggesting a plausible explanation for the increased DNA adduct
formation in RCC4 cells.
The level of DNA adducts is influenced by the balance between
the induction of the damage and its repair. Therefore, in addition
to the formation of adducts, we further analyzed whether loss of
VHL influences NER since the bulk of adducts are removed by this
DNA repair pathway (29). Our data indicate that the loss of VHL
had no effect on DNA repair gene expression. As DNA repair is
often regulated in multiple levels in addition to transcriptional
control, we sought to determine whether NER is functionally
impaired by HIFα stabilization. To determine the functionality
of NER, we used a previously validated modified comet assay,
which predominantly assesses the cellular capacity in the recog-
nition and incision phase of NER to remove bulky DNA adducts
(23). A dramatically lower repair capacity was observed in the
VHL-deficient RCC4 cells. Reduced NER capacity under hypoxic
conditions was previously demonstrated in mouse fibroblasts (30)
and in HIFα stabilized A549 cells (20). In the present study, we
show that lack of VHL in cells also results in a decreased repair
capacity. The reduced NER repair further explains the observed
higher BPDE-DNA adduct levels in VHL-deficient RCC cells.
In this study, we provide evidence that loss of VHL presum-
ably via the stabilization of HIF affects the BPDE-DNA adduct
levels in RCC cells and is in fact a double edged sword. Firstly,
the absence of VHL is associated with induced CYP1A1 mRNA
levels, which mediated a significant change in BaP-7,8-diOH lev-
els among other metabolites. This could significantly induce the
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formation of BPDE-DNA adduct levels. Secondly, the capacity to
repair DNA by NER is reduced in HIFα stabilized cells, thereby pre-
venting the repair of those BPDE-DNA adducts. Taken together,
these data indicate that loss ofVHL increases carcinogen genotoxi-
city in RCC in vitro and provides potential insight in the malignant
progression into RCC.
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